The complexity of atopic dermatitis (AD) continues to present a challenge in the appropriate selection of a mouse model because no single murine model completely recapitulates all aspects of human AD. This has been further complicated by recent evidence of the distinct AD endotypes that are dictated by unique patterns of inflammation involving Th1, Th2, Th17, and Th22 axes. A review of currently used mouse models demonstrates that while all AD mouse models consistently exhibit Th2 inflammation, only some demonstrate concomitant Th17 and/or Th22 induction. As the current understanding of the pathogenic contributions of these unique endotypes and their potential therapeutic roles expands, ongoing efforts to maximize a given mouse model’s homology with human AD necessitates a close evaluation of its distinct immunological signature.
Atopic dermatitis (AD) is a common, relapsing inflammatory skin condition characterized by pruritic, erythematous plaques and papules typically affecting the body’s flexural surfaces. While AD is known to emerge due to barrier dysfunction, aberrant immune activation, and genetic predisposition, a clear understanding of the pathogenesis of its varying clinical presentations remains under investigation. Current knowledge of AD’s multifaceted pathogenesis has been predicated on a diverse array of murine models that have played a pivotal role in delineating the functions of various susceptibility genes and exogenous triggers in the disease process.
However, the heterogeneity of AD disease in humans continues to present a challenge in selecting an appropriate mouse model for preclinical studies, given that no single model fully recapitulates all aspects of human AD. This has been further complicated by the recent identification of immunologically distinct human AD subtypes that occur due to differential inflammatory axis activation [1]. As the roles of these unique inflammatory patterns and their potential therapeutic implications in AD are further clarified, the selection of appropriate mouse models based on downstream immune pathways that modulate these clinically distinct subtypes is especially important in drug validation studies.
The current repository of AD murine models reflects a broad range of mechanisms used to induce eczematous dermatitis, including the use of exogenous agents, transgenic mice, and inbred mice. Several of these mechanisms, such as mucosa-associated lymphoid tissue lymphoma translocation protein 1 (MALT1) deficiency, fibroblast-specific inhibitor of nuclear factor kappa-beta subunit beta (Ikk2) deficiency, and Matt deficiency, have been only loosely correlated to human AD, and a clear understanding of their pathogenic contributions resulting in AD has yet to be fully delineated [2,3,4]. Nevertheless, the cutaneous inflammation observed in most models demonstrates significant overlap with key features found in human AD lesions, including elevated serum IgE, inflammatory infiltrate consisting of eosinophils, mast cells, and lymphocytes, increased epidermal thickness, hyperkeratosis, parakeratosis, acanthosis, and spongiosis [4,5,6].
More recently, transcriptomic analyses have measured similarities between highly differentially expressed genes in human AD and select murine models using the Meta-analysis derived atopic dermatitis transcriptome (MADAD), with data demonstrating most significant overlap with Adam17fl/flSox9Cre mice (34% overlap) and mice induced with IL-23 (36% overlap) [6,7,8]. This is followed by NC/Nga mice, demonstrating 18% overlap with the human AD transcriptome, and oxazolone-sensitized mice, with 17% overlap [7]. Similarly, gene set enrichment analysis conducted by Nunomura et al. (2019) on Ikk2-deficient (Ikk2∆NES) mice demonstrated a high degree of concordance with human AD in both upregulated (16 of 30) and downregulated (19 of 30) genes [3].
Consistent with the Th2 induction that broadly underscores all human AD endotypes, murine models invariably demonstrate Th2-biased immune response, with elevated levels of Th2-related cytokines: IL-4, IL-5, IL-13, and/or thymic stromal lymphopoietin (TSLP). Eight models (models 1–8) reported exclusively Th2 elevations, while two models (models 9–10) reported Th1 in addition to Th2 activation (Table 1). Four models (models 11–14) reported heightened Th2 and Th17 inflammation, three of which (models 12–14) also reported an increase in Th1-related cytokines (Table 2).
Model | Mechanism | Features | Immune Profile | Comparison to Human AD (If Applicable) |
References |
---|---|---|---|---|---|
(1) Stat6VT transgenic Mice | Transcriptionally active STAT6 downregulates loricrin and involucrin expression in the epidermis. | Hyperkeratosis, epidermal and dermal thickening, lymphocytic and eosinophilic infiltrate. | Th2 (IL-4) | Certain STAT6 intron SNPs with increased promoter activity were found to be associated with an increased risk of childhood AD. | [9,10,11] |
(2) K5-tTA-IL-13 mice | Transgenic mice with expression of IL-13 in the skin induced with the absence of a tetracycline | Dermal and epidermal thickening, spongiosis, hyperkeratosis, mononuclear and eosinophilic infiltration | Th2 (IL-13, TSLP) | [12] | |
(3) K5-TSLP | Tetracycline-inducible, skin-specific transgene expressing TSLP | Acanthosis, spongiosis, hyperkeratosis, dermal mononuclear infiltrate | Th2 (IL-4, IL-5) | [13] | |
(4) hK14mIL33tg | Transgenic mice with skin-specific expression of IL-33 driven by the human keratin 14 promoter. | Dermatitis with infiltrations of mast cells and eosinophils; increased IgE. | Th2 (IL-5, IL-13) | [14] | |
(5) Card11unm mice | Mice harbor Card11 single nucleotide variant that attenuates TCR/CD28 signaling to reduce the efficiency of NFκB signaling, resulting in the gradual expansion of Th2 cells. | Acanthosis, parakeratosis, and hyperkeratotic scale, and heavy infiltration by mast cells. | Th2 | Dermatitis-like symptoms reported in humans with Card11 deficiency (Demeyer et al., 2019) | [15] |
(6) Unmodulated mice with a mutation in Carma1/Card11 | Mice with a mutation in Carma1/Card11 have impaired NFκB and JNK activation. | High serum IgE, hyperkeratosis, predominantly mast cell infiltrate. | Th2 | Dermatitis-like symptoms reported in humans with Card11 deficiency (Demeyer et al., 2019) | [16] |
(7) Bioengineered mouse model | Bioengineered human skin equivalents grafted onto immunodeficient mice; intradermal injection of Th2 lymphocytes induce AD phenotype. | Epidermal thickening, dermal angiogenic response. | Th2 (TSLP) | Allows for selective introduction of specific cytokines and lymphocyte subsets to replicate specific inflammatory patterns. Potential interference with mouse cytokines and immune cell populations |
[17,18] |
(8) Diet-induced A | Dietary deficiency of unsaturated fatty acids may impair the skin barrier function | Epidermal thickening, mast cell and eosinophilic infiltrate, increased IgE | Th2 (IL-5, IL-13) | [19] | |
(9) EF1α transgenic mice | Transgenic mice are driven by the promoter Eμ-Lck overexpressing IL-31 | Increased pruritus, hyperkeratosis, acanthosis, mast cell proliferation, and inflammatory infiltrate | Th1 and Th2 | [20] | |
(10) _Jakspade/spade | A missense mutation in JAK1, resulting in hyperactivation. | Epidermal hyperplasia, mast cell/eosinophilic/lymphocytic infiltrate. | Th2 (IL-4, IL-5, IL-13) earlyTh1/Th2 (IFN-γ) late. | [21] |
Model | Mechanism | Features | Immune Profile | Comparison to Human AD (If Applicable) |
References |
---|---|---|---|---|---|
(11) Ikk2∆NES | Conditional Ikk2-deficient mice that do not express Ikk2 in the dermis fibroblasts of the face; develop AD spontaneously. | Keratinocyte proliferation, mast cell/eosinophilic infiltrate, increased IgE. | Th2 (IL-4, IL-5, IL-9, IL-13, TSLP, and Postn), Th17 (IL-17a) IL-10/20 family of genes (IL-10, IL-19, IL-20, and IL-24) No change in Th1 or Th22 |
Unclear relevance of pathogenesis; Ikk2-deficient humans do not display AD-like phenotype; the role of fibroblasts in AD is not characterized. No barrier dysfunction; the study reports an increase in filaggrin. The transcriptomic analysis shows broad similarities with human AD. |
[3] |
(12) MALT-1 knockout | MALT1 KO interferes with TCR-induced gene expression, lymphocyte proliferation, and regulatory T cell development, leading to Th2 expansion. | Acanthosis, hyperkeratosis, and parakeratotic scaling, as well as CD3+ T cell infiltration. | Th1 (IFN-γ) Th2 (IL-4) Th17 (IL-17) |
Dermatitis is reported in humans with MALT1 deficiency. (Demeyer et al., 2019) | [22] |
(13) Tmem79/Mattrin mutants | No expression of the protein mattrin; Impaired lamellar granular secretory system, leading to dysfunctional stratum corneum. | IL-17-dependent acanthosis, orthokeratosis, inflammatory infiltrate. Higher IgE response and TEWL levels in ma/ma after challenge with house dust mite allergen compared to FLG(ft/ft) mice. | Th1 (IFN-γ) Th2 (IL-4) Th17 (IL-17A) |
Matt gene mutation was found to have only a small but significant association in human AD risk. | [23,24,25,26] |
(14) 2,4-dinitrofluoro-benzene | Optimized DNFB dosing/scheduling to induce AD. | Lymphocytic and mast cell infiltrate epidermal hypertrophy and edema. | Th1 (IFN-γ) Th2 (IL-4) Th17 (IL-17A) |
DNFB is also used to model other proliferative skin disorders. | [27] |
Model | Mechanism | Features | Immune Profile | Comparison to Human AD (If Applicable) |
References |
---|---|---|---|---|---|
(15) K5-tTA-IL-22 mice | Transgenic mice with inducible expression of IL-22 in the skin | Thickening of the epidermis and dermis, spongiosis, hyperkeratosis, inflammatory cell infiltration (eosinophils, lymphocytes, macrophages, Langerhans cells, and mast cells), and dermal collagen accumulation | Th2 (IL-4, IL-13) Th17 (IL-17) Th22 (IL-22) Decreased IL-1 (low IFN-γ) |
[28] | |
(16) NC/Nga |
Spontaneous AD formation (pathogenesis undetermined) | Moderate epidermal hyperplasia with elongation of rete ridges, hyperkeratosis, increased mast cells, and eosinophils, increased IgE | Th2 (IL-4, IL-5)Th17/Th22 (IL-17A, IL-22) | 18% homology with human AD transcriptome | [29,30,31] |
(17) IL-23 injection in CCR2-deficient mice | IL-23 injection stimulates IL-22-dependent dermal inflammation and acanthosis; CCR2 blockade shunts immune response toward Th2 and away from Th1. | Acanthosis, hyperkeratosis, increased epidermal thickness, tissue eosinophilia. | Th1 (IFN-γ) Th2 (IL-13) Th17/Th22 (IL-17A, IL-22) |
37% homology with human AD transcriptome | [32] |
(18) Adam17fl/fl Sox9Cre | Adam17 deficiency in Sox9-expressing tissue causes dysbiosis, leading to AD. | Increased TEWL, eczematous skin lesions, increased IgE, mononuclear infiltrate. Dysbiosis with increased colonization of S. aureus. | Th1 Th2 (CCL17) Th17Th22 |
34% homology with human AD transcriptome. Adam17 deficiency in humans leads to AD-like phenotype. |
[8,33] |
(19) House dust mite allergen (HDM) | Epicutaneous sensitization to HDM | Epidermal hyperplasia, spongiosis, lymphocytic infiltrate, elevated serum IgE | Th2 (IL-4, IL-5, IL-13)- BALB/c and C57BL/6 miceTh17 (IL-17) Th22 (IL-22)- C57BL/6 mice |
[28,29] | |
(20) Ovalbumin (OVA) with mechanical barrier disruption | Tape-stripping followed by sensitization with topical or inhaled OVA. | Epidermal and dermal thickening with increased collagen deposition, infiltration of CD4+ T cells, and eosinophils, increased IgE. | Th1 (IFN-γ) Th2 (IL-4, IL-5, IL-13), Th17 (IL-17)- topical OVA Th17 (IL-17)- inhaled OVA Th22 (IL-22) |
11% homology with human AD transcriptome. | [29,34,35] |
(21) Chloromethyl-isothiazonilone (CMIT), methylisothia-zonilone (MIT) and Ovalbumin | CMIT/MIT with OVA leads to a more pronounced Th2 and Th17 response than OVA alone. | Increased TEWL, increased serum IgE, mast cell infiltrate. | Th2 (TSLP, IL-4, IL-6, IL-13) Th17 (IL-17A) |
Ability to differentially enhance Th17 to replicate certain endotypes. | [29,36] |
(22) Spontaneous recessive mouse mutant flaky tail (ft) | Expression of truncated profilaggrin with functionally absent filaggrin. | Diffuse orthokeratotic hyperkeratosis, acanthosis, infiltrating lymphocytes, eosinophils, mononuclear cells, increased TEWL. | Th1 (IFN-γ) Th2 (IL-4, IL-5, IL-13), Th17 (IL-17) upon percutaneous allergen exposure with OVA Th22 (IL-22) Differences in immune upregulation depending on mouse strain: C57BL/6: Th1. BALB/c: Th2/Th17 |
Filaggrin is the only functionally characterized gene in human AD. 4% homology with human AD transcriptome. |
[29,37,38] |
(23) Oxazolone (OXA) | Chronic exposure to OXA (vs. allergic contact dermatitis). | Dermal infiltration of Th2 lymphocytes, mast cells, eosinophils, elevated IgE, epidermal hyperplasia, decreased expression of filaggrin, loricrin, and involucrin. Decreased stratum corneum ceramide content, decreased stratum corneum hydration, transepidermal water loss, and impaired lamellar body secretion. | Th1 (IFN-γ) Th2 (IL-4, IL-13) Th17 (IL-17) Th22 (IL-22) |
17% homology with human AD transcriptome. | [29,34,39,40] |
(24) Vitamin D3 administration | Vitamin D3 or its analog MC903 (calcipotriol) induces overexpression of TSLP | Epidermal hyperplasia, dermal inflammatory infiltrate of eosinophils, CD3, CD4, CD11c, mast cells | Th1/Th2 mixed (TSLP, IL-4, IL-5, IL-13, IL-31, IL-10, IL-8, IFN-γ, TNF) Th17 (IL-17) Th22 (IL-22) |
[29,41] |
Model | Therapeutic Agent | Class | Effects on Mice | Reference |
---|---|---|---|---|
NC/Nga | Dexamethasone | Corticosteroid | Reduction of Th2- (IL-4, IL-5) and Th17-related (IL-17A) cytokines. Reduction in tissue swelling and immune cell infiltration. | [42] |
NC/Nga | Delgocitinib (JTE-052) | JAK inhibitor | Improved clinical score, decreased TEWL, restoration of hygroscopic amino acids needed for stratum corneum hydration | [48] |
NC/Nga | Tacrolimus | Calcineurin inhibitor | Reduction of Th1- (IFN-γ), Th2- (IL-5, IL-13), Th17-related (IL-17) cytokines | [44] |
MC903 (calcipotriol) | Crisaborole | PDE4 inhibitor | Reduction in ear thickness and skin swelling. | [46] |
MC903 (calcipotriol) | Compd3 | Novel PDE4 inhibitor | Reduction in TSLP expression | [47] |
Oxazolone-challenged | Pimecrolimus Methylprednisolone | Calcineurin inhibitor Corticosteroid |
Decrease in TEWL and increased stratum corneum hydration Reduced expression of IL-1α, TNF-α, PAR-2, and TSLP |
[43] |
Ikk2∆NES | Tacrolimus Tofacitinib Stattic |
Calcineurin inhibitor JAK inhibitor Stat3 inhibitor | Partial decrease in the infiltration of leukocytes and eosinophils; partial decrease in epidermal swelling. | [3] |
DNFB-challenged | Cyclosporine | Calcineurin inhibitor | Partial suppression of IL-13 and TNF-α upregulation. No effect on inflammatory changes. | [45] |
DNFB-challenged | Delgocitinib (JTE-052) | JAK inhibitor | Reduction in IL-4, IL-13, and TNF-α expression. Reduction in acanthosis, spongiosis, and inflammatory infiltrate. | [45] |
House dust mite allergen | Cyclosporine | Calcineurin inhibitor | No effect on ear thickness | [45] |
House dust mite allergen | Delgocitinib (JTE-052) | JAK inhibitor | Reduction in ear thickness with greater efficacy than cyclosporine. | [45] |
House dust mite allergen | Tofacitinib | JAK inhibitor | Diminished IL-1β, TNF-α, TSLP, IL-4, IL-13 | [49] |
Human skin graft model | Delgocitinib (JTE-052) | JAK inhibitor | Increased FLG protein expression | [48] |
This entry is adapted from the peer-reviewed paper 10.3390/jcm10040613